Even though slightly more than half of the US population is female, medical research historically has neglected the health needs of women, other than reproductive issues. However, during the past two decades, there have been major changes in government and private support of women’s health research -- in policies, regulations, and the organization of research efforts. In a recent Institute of Medicine (IOM) report, the Washington DC-based institute found that women’s health research has contributed to significant progress over the past 20 years in lessening the burden of disease and reducing deaths from some conditions for women, while other conditions have seen only moderate change or even little or no change.
This Kalorama Information report, Diagnostic Markets for Women's Health provides insight into this key area of testing. The following tests are among those covered in this report.
Market size and forecast are provided for these testing markets.Women make more than 75% of the health care decisions in American households and spend almost two of every three health care dollars. Women also make more than 65% of physician visits, 62% of prescription drug purchases, and 76% of the nursing home population. The life expectancy of women is longer than for men and is climbing steadily due to advancements in medicine. Yet, female health is an area that has much room for improvement both in the development of products and the treatment of diseases.
This report analyzes the current and potential world markets for key diagnostic tests targeted at women’s health. This report generally forecasts future market growth for these tests to 2015. Market segments covered include the world and North American markets. This report also reviews the nature and direction of research and trends, and gives insight into some issues facing the industry.
The report profiles several key companies, including large companies that have made names for themselves in the field, as well as smaller firms with market niches. These companies are involved in developing and marketing over the counter (OTC), point of care (POC) in vitro diagnostic (IVD) tests and screening systems. Some of the companies profiled include
All Kalorama reports advertise the single user price. Use is limited to one user. We also feature department and global pricing for reports that we be utilized by more than one user at your company. Please consult ask your sales representative or select the correct license on our website.
For Kalorama's take on the healthcare news of the week, based on our analysis of healthcare markets, follow Kalorama Information's Key Point Blog at http://kaloramakeypoint.blogspot.com/
Personalized medicine and improved diagnostics hold particular promise for improving cancer diagnosis and treatment, where small genetic differences can often impact prognosis and outcomes. Breast cancer is an area where the targeted therapy concept has found real applications and according to healthcare market research publisher Kalorama Information's report, Women's Health Diagnostic Testing Markets, patients are already beginning to benefit from tests that help tailor treatment of the more than 200,000 cases diagnosed annually.
"Even though slightly more than half of the US population is female, medical research historically has neglected the health needs of women, other than reproductive issues," said Bruce Carlson, publisher of Kalorama Information. "That's changing, as campaigns to increase breast cancer awareness have resulted in more funding, which in turn has meant better screening, treatments and survival rates for women."
Meanwhile, the revolution in bioinformatics has allowed scientists to mine genetic information to derive new and hopefully better markers for breast cancer, as well as for cardiac disease, diabetes and autoimmune disorders. This has contributed to advances in immunoassays and nucleic acid tests.
Kalorama notes that today physicians routinely run tests to determine if a patient has human epidermal growth factor receptor-2 (HER2) positive breast cancer, which is more aggressive but responds better to targeted treatment. HER2-positive patients must undergo a different treatment regimen than those with HER2-negative breast cancer.
Clarient, which was purchased by GE Healthcare in 2010, launched a tool to aid physicians with prognosis and decision-making in treating breast cancer patients beyond the HER2 question. The Clarient Insight Dx Breast Cancer Profile uses a combination of pathology risk factors and molecular markers to categorize patients with early-stage, hormone-receptor-positive breast cancer as either at high or low risk of recurrence.
"A $500 test to determine if a breast cancer patient will benefit or not from a specific chemotherapy drug seems a small price to pay when treatment that will cost $25,000 to $80,000," says Carlson.
Women's Health Diagnostic Testing Markets, details and analyzes the current and potential world markets for key diagnostic tests targeted at women's health. Pregnancy and ovulation testing, bone density testing, pap smears, mammography, and ultrasound are among the tests that target female health. This report also reviews the nature and direction of research and trends, and gives insight into some issues facing the industry.